Thousand Oaks Biologics Unveils Innovative CRDMO Solutions at CPHI Frankfurt 2025

Frankfurt, Germany – October 29, 2025
Thousand Oaks Biologics, a prominent Contract Research and Development Manufacturing Organization (CRDMO) based in Asia, has announced its active participation in CPHI Frankfurt 2025, which took place from October 28 to 30. The company is showcasing its impressive integrated service platform at Booth 4.1H54 in the Bioproduction Zone. Visitors are invited to explore how Thousand Oaks harnesses industrial media supply and artificial intelligence (AI) alongside innovative drug discovery technologies, positioning itself as a trusted player in the biopharmaceutical landscape.

Thousand Oaks Biologics is making waves in the innovative drug sector, particularly with antibody-drug conjugates (ADCs), and addressing crucial challenges in biopharmaceutical development. With its end-to-end CRDMO model, the company is focused on tackling key industry issues such as research and development efficiency, cost management during scale-up, and regulatory compliance. By maintaining a self-sufficient supply of essential raw materials and implementing rigorous quality management systems, Thousand Oaks is committed to supporting over 500 biopharmaceutical firms to expedite their drug development processes.

Industrial Media Supply System and Innovation

One of the standout features of Thousand Oaks Biologics is its pioneering serum-free media technology, which has enabled the company to maintain autonomous production of core raw materials. The intelligent manufacturing facility ensures a seamless transition from laboratory-scale customization to full commercial supply. Moreover, a collaborative effort with Busan Metropolitan City in South Korea and KCell Biosciences is reinforcing its global supply chain and creating a cost-competitive vertically integrated model.

The Integrated ADC CMC Technology Platform, powered by AI, enhances productivity by offering a co-located layout for naked antibodies, ADC drug substances, and finished ADC products all within the same facility. This strategic move significantly streamlines both development and technology transfer processes. The Shanghai ADC production site, which recently passed its European Qualified Person (QP) audit, features production lines capable of handling a range of volumes, from 200L to 2000L for antibody drug substances and 50L to 500L for ADC conjugate drug substances—thereby supporting a smooth transition from clinical trials to commercialization.

Addressing RD Challenges with Comprehensive Support

The Ginspire initiative from Thousand Oaks Biologics tackles the various complexities associated with innovative molecule development, enhancing research and development (R&D) effectiveness. This program provides a wide array of early-stage services, such as candidate screening, IND submission processes, molecule design and optimization, and comprehensive pharmacology studies. Through early-stage sample preparation, structural characterization, and the development of innovative formulations, Thousand Oaks creates an efficient continuum from early-stage R&D to production.

Global Strategic Vision

Thousand Oaks Biologics is evolving its role in the biopharmaceutical sector by transitioning from a service provider to a strategic partner. The company has launched an ADC Early-Stage Support Program and is collaborating with partners in Europe to enhance value co-creation.

Dr. Luo Shun, Chairman of Thousand Oaks Biologics, remarked, "Global biopharmaceutical clients are looking for more than just manufacturing capabilities; they seek comprehensive partnerships that encompass the entire cycle from concept to patient delivery. Our CRDMO model, EU-compliant qualifications, and the establishment of global hubs empower us to address core challenges facing the industry while improving cost efficiency and ensuring better access to biologics for patients around the world."

For those eager to connect with Thousand Oaks Biologics, the team will be available at Booth 4.1H54 during the event. Interested parties can also reach out via email at [email protected].

Thousand Oaks Biologics is not just a company; it stands as a crucial ally in the journey of biopharmaceutical innovation, leading the way with their advanced CRDMO solutions and a commitment to improving healthcare outcomes globally.